Patents by Inventor Micheal Gaul

Micheal Gaul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Indazole derivatives useful as glucagon receptor antagonists
    Patent number: 11098016
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: August 24, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • 5-fluoro-c-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators
    Patent number: 11014917
    Abstract: The present invention is directed to 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: May 25, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Gee-Hong Kuo, Micheal Gaul
  • INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS
    Publication number: 20200377462
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Application
    Filed: August 12, 2020
    Publication date: December 3, 2020
    Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators
    Patent number: 10815210
    Abstract: The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 27, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Micheal Gaul, Gee-Hong Kuo, Guozhang Xu, Yin Liang
  • 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS
    Publication number: 20200291004
    Abstract: The present invention is directed to 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.
    Type: Application
    Filed: June 2, 2020
    Publication date: September 17, 2020
    Inventors: Guozhang Xu, Gee-Hong Kuo, Micheal Gaul
  • Indazole derivatives useful as glucagon receptor antagonists
    Patent number: 10774048
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: September 15, 2020
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators
    Patent number: 10696662
    Abstract: The present invention is directed to 5-fluoro-C-(aryl or hetercyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: June 30, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Gee-Hong Kuo, Micheal Gaul
  • BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS
    Publication number: 20190367469
    Abstract: The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.
    Type: Application
    Filed: November 8, 2017
    Publication date: December 5, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Micheal Gaul, Gee-Hong Kuo, Guozhang Xu, Yin Liang
  • INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS
    Publication number: 20190218186
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Application
    Filed: January 8, 2019
    Publication date: July 18, 2019
    Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • Indole derivatives useful as glucagon receptor antagonists
    Patent number: 10251864
    Abstract: The present invention is directed to indole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: April 9, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Micheal Gaul, Guozhang Xu, Bao-Ping Zhao
  • Indazole derivatives useful as glucagon receptor antagonists
    Patent number: 10214493
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: February 26, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Micheal Gaul, Guozhang Xu, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS
    Publication number: 20190055226
    Abstract: The present invention is directed to 5-fluoro-C-(aryl or hetercyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 21, 2019
    Inventors: Guozhang Xu, Gee-Hong Kuo, Micheal Gaul
  • Indazole derivatives useful as glucagon receptor antagonists
    Patent number: 10000473
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: June 19, 2018
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Micheal Gaul, Guozhang Xu, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS
    Publication number: 20180065955
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Application
    Filed: September 5, 2017
    Publication date: March 8, 2018
    Inventors: Micheal Gaul, Guozhang Xu, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS
    Publication number: 20180065934
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Application
    Filed: September 5, 2017
    Publication date: March 8, 2018
    Inventors: Micheal Gaul, Guozhang Xu, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS
    Publication number: 20180064686
    Abstract: The present invention is directed to indole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Application
    Filed: September 5, 2017
    Publication date: March 8, 2018
    Inventors: Micheal Gaul, Guozhang Xu, Bao-Ping Zhao
  • Dual SGLT1/SGLT2 inhibitors
    Patent number: 9012412
    Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein A, R1, R2, R3, R4, and R5 are as defined herein, useful as dual SGLT1/SGLT2 inhibitors.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: April 21, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Micheal Gaul, Gee-Hong Kuo, Guozhang Xu, Bao-Ping Zhao
  • DUAL SGLT1/SGLT2 INHIBITORS
    Publication number: 20140256657
    Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein A, R1, R2, R3, R4, and R5 are as defined herein, useful as dual SGLT1/SGLT2 inhibitors.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 11, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Micheal Gaul, Gee-Hong Kuo, Guozhang Xu, Bao-Ping Zhao
  • Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-? modulators
    Patent number: 8796256
    Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalac
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: August 5, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gilles Bignan, Wing Cheung, Micheal Gaul, Hui Huang, Xun Li, Raymond Patch, Sharmila Patel, Mark Player, Guozhang Xu, Bao-Ping Zhao, Jian Liu
  • Aminothiazolones as estrogen related receptor-alpha modulators
    Patent number: 8445690
    Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalac
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: May 21, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gilles Bignan, Micheal Gaul, Guozhang Xu, Bao-Ping Zhao